Table 5.
Key methodological characteristics of HTAs of biosimilars
| HTA reports | Immunogenicity was considered | Risk of switching/interchangeability was considered | Extrapolation of one or more condition was considered | Educational approach about biosimilars was considered | Statement in favour, against or not declared about the adoption/reimbursement of biosimilar | ||
|---|---|---|---|---|---|---|---|
| Statement in favour | Statement against | Not declared | |||||
|
Full HTA (n = 2) |
1 | 1 | 1 | 1 | 2 | 0 | 0 |
|
Mini-HTA (n = 4) |
4 | 4 | 4 | 4 | 4 | 0 | 0 |
|
Rapid review (n = 64) |
39 | 13 | 42 | 14 | 51 | 0 | 13 |
HTA health technology assessment